RxDoctor Payments Data

Allison Bardes, MD

Ophthalmology · Buckhannon, WVNPI 1144586942

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Rxsight Inc at 55.1% of the total. 2025 is the largest year on record at $3,259, more than ten times the $201 reported in 2019.

$5,622in general payments, 2019–2025

Across 55 payments — averaging $102.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$3K
  • Alcon$2K
  • Johnson & Johnson Surgical Vision, Inc.$197
  • Mallinckrodt Hospital Products Inc.$195
  • Sight Sciences, Inc.$174
  • Regeneron Healthcare Solutions, Inc.$114
  • plus $292 from 8 others

What the payments were for

  • Consulting fees$3,00053%
  • Travel & lodging$72413%
  • Food & beverage$1,77932%
  • Education$1002%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,622 in reported general payments places this provider in the 80th percentile of 85 ophthalmology providers in West Virginia.

See all ophthalmology providers in West Virginia

Medicare billing

Part B allowed, 2024
$234,915
Medicare patients
542
Services billed
2,384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine34$35,332
LumiganBimatoprost38$13,265
Prednisolone Acetate301$8,959
CombiganBrimonidine Tartrate/Timolol26$8,302
Alphagan PBrimonidine Tartrate25$8,285
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol33$7,817
Travoprost23$6,572
Latanoprost387$4,728
Ketorolac Tromethamine174$2,877
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat126$2,719
Ofloxacin175$2,107
Timolol Maleate149$1,471
MoxifloxacinMoxifloxacin Hcl58$1,332
Brimonidine Tartrate78$1,279
Dorzolamide Hcl44$772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$40$65,184123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 85 ophthalmology providers in West Virginia.

Other ophthalmology in Buckhannon

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →